Inducible gene inactivation in neurons of the adult mouse forebrain by Erdmann, Gitta et al.
BioMed  Central
Page 1 of 10
(page number not for citation purposes)
BMC Neuroscience
Open Access Research article
Inducible gene inactivation in neurons of the adult mouse forebrain
Gitta Erdmann, Günther Schütz* and Stefan Berger
Address: Division Molecular Biology of the Cell I, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, 
Germany
Email: Gitta Erdmann - g.erdmann@dkfz.de; Günther Schütz* - g.schuetz@dkfz.de; Stefan Berger - s.berger@dkfz.de
* Corresponding author    
Abstract
Background: The analysis of the role of genes in important brain functions like learning, memory
and synaptic plasticity requires gene inactivation at the adult stage to exclude developmental
effects, adaptive changes or even lethality. In order to achieve temporally controlled somatic
mutagenesis, the Cre/loxP-recombination system has been complemented with the tamoxifen-
inducible fusion protein consisting of Cre recombinase and the mutated ligand binding domain of
the human estrogen receptor (CreERT2). To induce recombination of conditional alleles in neurons
of the adult forebrain, we generated a bacterial artificial chromosome-derived transgene expressing
the CreERT2 fusion protein under control of the regulatory elements of the CaMKIIα gene
(CaMKCreERT2 transgene).
Results:  We established three mouse lines harboring one, two and four copies of the
CaMKCreERT2 transgene. The CaMKCreERT2 transgene displayed reliable and copy number-
dependent expression of Cre recombinase specifically in neurons of the adult forebrain. Using Cre
reporter mice we show very low background activity of the transgene in absence of the ligand and
efficient induction of recombination upon tamoxifen treatment in all three lines. In addition, we
demonstrate in mice harboring two conditional glucocorticoid receptor (GR) alleles and the
CaMKCreERT2 transgene spatially restricted loss of GR protein expression in neurons of the adult
forebrain upon tamoxifen treatment.
Conclusion: This is to our knowledge the first approach allowing highly efficient inducible gene
inactivation in neurons of the adult mouse forebrain. This new approach will be a useful tool to
dissect the function of specific genes in the adult forebrain. Effects of gene inactivation on pre- and
postnatal brain development and compensatory mechanisms elicited by an early onset of gene
inactivation can now be excluded.
Background
The generation of mouse mutants harboring targeted inac-
tivation of desired genes using homologous recombina-
tion in embryonic stem cells is a powerful tool to analyze
their role in complex brain functions such as learning and
memory, synaptic plasticity as well as neurogenesis and
neuronal cell death [1-3]. However, inactivation of genes
in the germline often results in a lethal phenotype that
prevents further analysis of the targeted gene in the adult
brain.
To bypass early lethality and to analyze functions of a
gene particularly in the adult brain the Cre/loxP-recombi-
nation system, that allows to conditionally ablate a
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defined gene, was implemented. In the Cre/loxP-recombi-
nation system the bacteriophage P1 Cre recombinase is
expressed in a cell-type specific manner. In the Cre
expressing cells the recombinase mediates excision of an
essential part of the targeted gene that has been flanked by
two loxP recognition sequences in the same orientation
[4,5].
To drive the expression of Cre in the brain, in most cases
short promotor fragments of genes with desired expres-
sion pattern have been cloned in front of a Cre cassette in
a plasmid [6-8]. Since plasmid-derived transgenes show
copy number-independent and often mosaic and ectopic
expression [9,10] the use of BAC (bacterial artificial chro-
mosome)- or YAC (yeast artificial chromosome)-derived
transgenes is in favor. In contrast to plasmids, BAC and
YAC vectors harbor large genomic regions containing
almost all regulatory elements of the gene locus that was
chosen to drive Cre expression. However, a given gene
locus may not only be expressed in the adult brain, but
also during pre- and postnatal development [11]. To over-
come the necessity to find a gene locus that is active only
at a desired time-point during development or at the adult
stage fusion proteins consisting of Cre recombinase and a
mutated ligand-binding domain (LBD) of a steroid hor-
mone receptor have been developed to achieve ligand-
dependent Cre activity. The mutated LBD retains the
fusion protein in the cytoplasm and upon binding of a
synthetic ligand it translocates into the nucleus, where it
mediates the excision of the loxP-flanked DNA sequence
[12-15]. It has been shown in vitro and in vivo that the
CreERT2 is the most potent Cre fusion protein with low
leakiness and highly efficient induction [13,16]. The
CreERT2 fusion protein was so far applied in peripheral
cell-types/tissues [17-19] and within the nervous system
in oligodendrocytes and Schwann cells [20], astrocytes
[21-23] and neural stem cells [24]. The verification of
CreERT2-mediated recombination was only performed
using Cre reporter mice. Cre reporter data are very helpful
to detect ligand-independent (background) activity of the
Cre and robust induction of recombination, but this type
of analysis does not allow to assess incomplete induction.
To analyze the extent of gene inactivation, expression
analysis of the protein encoded by the targeted gene is
mandatory.
In order to target neurons in the adult brain that partici-
pate in important brain functions like learning, memory
and long term potentiation, we have chosen the CaMKIIα
gene regulatory elements to drive CreERT2 expression in
the forebrain including limbic structures like hippocam-
pus and amygdala. We introduced the CreERT2 fusion pro-
tein in frame at the ATG of the CaMKIIα gene present on
a large genomic fragment in a BAC vector using homolo-
gous recombination in bacteria. The established trans-
genic mouse lines (CaMKCreERT2) displayed copy
number-dependent, forebrain-specific expression of the
Cre recombinase. Using this transgene we show efficient
forebrain-specific induction of recombination upon
tamoxifen treatment with very low background activity in
absence of the ligand restricted to the hippocampus.
Unlike previous studies utilizing CreERT2  mediated
recombination in the brain, we demonstrate for the first
time by expression analysis of the protein encoded by the
targeted gene, the high efficiency of this inducible gene
inactivation system.
Results
Copy number-dependent expression of the CreERT2-fusion 
protein in the adult mouse hippocampus
To achieve inducible recombination of conditional alleles
in neurons of the adult brain, we generated a BAC-derived
transgene expressing the CreERT2 fusion protein under the
control of the regulatory elements of the mouse CaMKIIα
gene (CaMKCreERT2). The CreERT2 fusion protein consists
of the Cre recombinase and a mutated ligand binding
domain (LBD) of the human estrogen receptor (ER)
[13,16]. The ER-LBD contains a nuclear localization signal
that is unmasked upon ligand binding. Two point muta-
tions in the ER-LBD allow binding of the synthetic ligand
tamoxifen and prevent activation of the CreERT2  by
endogenous estradiol. Therefore, the unliganded form of
the CreERT2 fusion protein resides in the cytoplasm and
upon tamoxifen binding it translocates into the nucleus
and mediates site-specific recombination. We selected a
BAC vector harboring a genomic insert containing the
CaMKIIα gene locus with a 43 kb 5'upstream and a 100 kb
3'downstream region from the mouse genome project
[25]. To obtain the CaMKCreERT2 transgene we inserted
the coding sequence for the CreERT2 fusion protein at the
ATG of the CaMKIIα locus (Fig. 1A) by homologous
recombination in bacteria [26]. Using an equivalent
genomic fragment containing the CaMKIIα gene our
group has already generated a constitutive transgene
(CaMKCre) that expresses the Cre recombinase under the
control of the regulatory elements of the mouse CaMKIIα
gene [27].
The modified genomic insert was released and separated
from the BAC backbone and then introduced into the
mouse germline by oocyte injection. Transgenic founder
animals were identified by PCR and dot blot analysis of
tail DNA. The F1 progeny was used to determine the copy
number of the transgene by Southern blot (Fig. 1H–J).
Three lines harboring either one, two or four copies of the
transgene were chosen for further analyses. We investi-
gated the expression and nuclear translocation of the
CreERT2  fusion protein upon tamoxifen treatment by
immunohistochemistry on hippocampal vibratome sec-
tions using an anti-Cre antibody. Transgenic animals wereBMC Neuroscience 2007, 8:63 http://www.biomedcentral.com/1471-2202/8/63
Page 3 of 10
(page number not for citation purposes)
injected with either tamoxifen or vehicle 12 hours before
dispatch. In the vehicle-treated animals the CreERT2 pro-
tein was located in the cytoplasm (Fig. 1B, D and 1F),
whereas tamoxifen-treated animals displayed nuclear
localization of the Cre recombinase in the hippocampus
(Fig. 1C, E and 1G). In addition, copy number-dependent
expression was observed, the four-copy line showed
stronger expression of the CreERT2 fusion protein than the
two-copy line which displayed a stronger Cre expression
in the hippocampus than the one-copy line (Fig. 1B–J).
Nuclear translocation and copy number-dependent
CreERT2  expression was also observed in other brain
regions, e.g. cortex (data not shown).
Targeted recombination in adult forebrain regions upon 
tamoxifen induction
To assess the ERT2-mediated control of Cre activity in
absence of the ligand in forebrain neurons and to examine
the efficiency of tamoxifen-induced Cre-mediated recom-
bination, CaMKCreERT2  mice with different transgene
copy numbers were crossed with ROSA26 Cre reporter
mice (R26R allele) [28] to obtain R26R/CaMKCreERT2
mice. The Cre reporter line harbors a knock-in of a lacZ
gene preceded by a stop cassette, flanked by two recogni-
tion sequences (loxP) for the Cre recombinase, in the
ROSA26 locus. Upon tamoxifen treatment CreERT2 trans-
locates into the nucleus and deletes the stop cassette
thereby permitting β-galactosidase expression.
R26R/CaMKCreERT2 mice were injected twice per day with
either tamoxifen or vehicle for five consecutive days.
Whole mount samples of the adult brain from the one-,
two- or four-copy line were analyzed for β-galactosidase
activity. Determination of CreERT2 activity in absence of
the ligand revealed that ten weeks old vehicle-injected ani-
mals of all three transgenic lines showed very little β-
galactosidase activity within the hippocampus only.
Using whole mount staining we could not detect substan-
tial differences between one, two and four copies of the
transgene (Fig. 2A, two-copy line). After tamoxifen treat-
ment in all three lines β-galactosidase activity was most
prominent in the cortex and hippocampus. The one-copy
line showed less intense staining than the two- and four-
copy lines. However, no apparent difference was observed
between the two-copy and the four-copy line (data not
shown). In all three lines no β-galactosidase activity was
detected in other organs than the brain after tamoxifen
induction (data not shown).
Since the use of the minimal number of transgene copies
that allow efficient recombination upon tamoxifen induc-
tion is desired, we only characterized for the two-copy line
the activity in absence of tamoxifen ("background") in
more detail. At the cellular level, using cryosections, vehi-
cle-treated R26R/CaMKCreERT2 mice of the two-copy line
displayed only few granular neurons in the dentate gyrus
and even less pyramidal neurons in the CA1 region of the
hippocampus that underwent recombination of the
reporter allele (Fig. 2D–F).
In order to compare the spatial activity of the inducible
CaMKCreERT2 transgene with the constitutive CaMKCre
Copy number-dependent transgene expression and  tamoxifen-dependent nuclear translocation of the CreERT2- fusion protein in neurons of the adult hippocampus Figure 1
Copy number-dependent transgene expression and 
tamoxifen-dependent nuclear translocation of the 
CreERT2-fusion protein in neurons of the adult hip-
pocampus. (A) The cassette encoding the CreERT2-fusion 
protein was inserted in frame at the ATG of the CaMKIIα 
gene present on a large DNA fragment of a BAC vector con-
taining mouse genomic DNA by homologous recombination 
in bacteria. The genomic insert of the BAC vector contained 
a 43 kb 5'-upstream and a 100 kb 3'-downstream region of 
the CaMKIIα gene. (B-G) Immunohistochemical staining of 
pyramidal neurons in the hippocampal CA1 region of 
CaMKCreERT2 transgenic animals with different transgene 
copy numbers using an antibody against Cre recombinase 
revealed non-nuclear localization of the Cre recombinase in 
vehicle-injected animals (B, D, F) and nuclear localization in 
animals 12 hours after injection of 1 mg tamoxifen (C, E, G). 
The CaMKCreERT2 transgene copy number was determined 
by Southern blot analysis using a probe that detects restric-
tion fragments of different sizes for the endogenous CaM-
KIIα gene (upper band) and the CaMKCreERT2 transgene 
(lower band) (H, I, J).BMC Neuroscience 2007, 8:63 http://www.biomedcentral.com/1471-2202/8/63
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transgene,  β-galactosidase stained brain whole mount
samples of adult R26R/CaMKCre mice were analyzed as
well. Both, R26R/CaMKCreERT2 (two copies) and R26R/
CaMKCre mice showed extensive recombination in hip-
pocampus and cortex (Fig. 2B and 2C). However, the con-
stitutive transgene caused additional recombination in
olfactory bulbs, striatum and cerebellum (Fig. 2C). Immu-
nohistochemical staining for Cre revealed a strong expres-
sion of CreERT2  protein in those regions showing
recombination in R26R/CaMKCreERT2 mice (e.g. hippoc-
ampus, cortex). As shown for the constitutive CaMKCre
line at the adult stage [27], we could detect only very low
level of CreERT2 expression in striatum and thalamus and
no expression in cerebellum of CaMKCreERT2 transgenic
mice (data not shown). Using Cre reporter mice we did
not observe Cre-mediated recombination in any of these
regions after tamoxifen application (data not shown).
To quantify and compare recombination evoked by the
constitutive CaMKCre transgene and the CaMKCreERT2
transgene, induced with 1 mg tamoxifen twice per day for
five consecutive days, at the DNA level by Southern blot,
CreERT2 fusion protein expression driven by the regulatory elements of the CaMKIIα gene allows targeting of specific regions  in the adult brain upon tamoxifen treatment Figure 2
CreERT2 fusion protein expression driven by the regulatory elements of the CaMKIIα gene allows targeting of 
specific regions in the adult brain upon tamoxifen treatment. (A, B) β-galactosidase staining of brain slices revealed 
that animals harboring a ROSA26 Cre reporter allele and the CaMKCreERT2 transgene (R26R/CaMKCreERT2, two copies) 
show low Cre activity in absence of the ligand only within the hippocampus (Hc) (A), but strong staining within the cortex (Co) 
and hippocampus (Hc) upon tamoxifen treatment (B). (D-F) Analysis of β-galactosidase positive neurons using cryosections of 
the hippocampus of R26R/CaMKCreERT2 mice revealed sparse recombination in the granular neurons of the dentate gyrus 
(DG) and in hippocampal neurons of the CA1 region in the absence of tamoxifen. (C) β-galactosidase staining of a brain slice 
isolated from an animal harboring a ROSA26 Cre reporter allele and the constitutive CaMKCre transgene (R26R/CaMKCre) 
revealed recombination in the hippocampus and cortex as well as recombination in olfactory bulbs (Ob), striatum (St) and cer-
ebellum (Ce). (G-I) Recombination of a conditional GR allele achieved using the CaMKCreERT2 transgene (two copies) plus 
tamoxifen treatment (2 × 1 mg tamoxifen for five consecutive days) is comparable to recombination obtained using the consti-
tutive CaMKCre transgene. Recombination levels detected in distinct brain regions (Co, Hc, Ht = hypothalamus, Ce) of mice 
heterozygous for the conditional GR allele (GRflox) and either the constitutive (GRflox/wt/CaMKCre) (I) or the inducible (GRflox/
wt/CaMKCreERT2, tamoxifen-treated) (G) Cre transgene (two copies) were determined using Southern blot analysis. The 
Southern blot strategy is depicted in (H), black boxes represent exons three and four of the GR gene, the arrowheads the loxP 
sites and S marks SacI recognition sites. The probe detects in case of the GRflox and the GRwt allele a DNA fragment of similar 
size and in case of the GRnull allele a smaller DNA fragment. The bands were quantified by phosphoimager and the percentage 
of recombination for each region is indicated. Animals for Cre reporter and Southern blot analysis were treated with 1 mg 
tamoxifen or vehicle twice a day for five consecutive days and sacrificed ten days after the last injection.BMC Neuroscience 2007, 8:63 http://www.biomedcentral.com/1471-2202/8/63
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we generated animals heterozygous for the conditional
GR allele (GRflox) [29] harboring either the constitutive
(GRflox/wt/CaMKCre) or the inducible Cre (GRflox/wt/
CaMKCreERT2, two copies) transgene respectively. The
analysis of adult samples of different brain regions
revealed that the areas showing recombination using Cre
reporter mice (e.g. hippocampus and cortex) display a
comparable degree of recombination for both transgenes
(Fig. 2G–I). In case of the cerebellum we detected, as
expected from the Cre reporter data, no recombination of
the GRflox allele for the induced CaMKCreERT2 transgene,
but distinct recombination for the constitutive CaMKCre
transgene (Fig. 2G and 2I).
Ablation of GR protein expression in the adult brain upon 
tamoxifen treatment using the CaMKCreERT2 transgene
To demonstrate at the cellular level that the tamoxifen-
induced CreERT2-mediated recombination of a targeted
gene results in complete protein loss within specific pop-
ulations of neurons, we generated GRflox/flox/
CaMKCreERT2 (GRCaMKCreERT2) mice with two copies of the
CaMKCreERT2 transgene. Eight weeks old GRCaMKCreERT2
mice were treated twice per day either with 1 mg
tamoxifen or vehicle for five consecutive days and were
sacrificed ten days after tamoxifen application. In addi-
tion, the mice were injected with 1 mg tamoxifen 12 hours
before dispatch to visualize Cre expression. Immunohis-
tochemistry revealed CreERT2 expression in the cortex, the
hippocampus (Fig. 3C, F and 3I) as well as in the hypoth-
alamic paraventricular nucleus (PVN) (Fig. 3L) and baso-
lateral amygdala, whereas the central amygdala was
spared (Fig. 3O). Accordingly, in neurons of these regions
with strong CreERT2 expression, tamoxifen-treated ani-
mals show loss of GR protein (Fig. 3B, E, H, K and 3N)
compared to vehicle-treated mice (Fig. 3A, D, G, J and
3M). Analysis of CreERT2 and GR protein expression in
other forebrain structures revealed strong CreERT2 expres-
sion and the corresponding GR protein loss in the lateral
septum and in the medial preoptic area, whereas in the
striatum only weak Cre expression and no visible loss of
GR protein were detectable (data not shown). Even
though Cre reporter data revealed CreERT2  activity in
absence of the ligand in the hippocampus, the back-
ground activity is much too low to allow the detection of
a visible loss of GR protein expression in vehicle-treated
GRCaMKCreERT2 mice in comparison to wild-type animals
(data not shown).
To identify neuronal subtypes that are targeted in the cor-
tex by the CaMKCreERT2 transgene, we performed immu-
nohistochemical double-stainings for CreERT2  and
markers for the two major neuronal subtypes present in
the cortex. GABAergic interneurons were identified by
GAD65/67 expression and glutamatergic neurons by
VGLUT1 expression. We detected no CreERT2  protein
expression in GABAergic interneurons, whereas expres-
sion of CreERT2 was present in glutamatergic neurons
(data not shown).
Ablation of GR protein expression in neurons of the adult  brain upon tamoxifen treatment Figure 3
Ablation of GR protein expression in neurons of the 
adult brain upon tamoxifen treatment. Vibratome-sec-
tions of mice homozygous for a conditional GR allele (GRflox) 
and heterozygous for the CaMKCreERT2 transgene 
(GRCaMKCreERT2 mice) have been analyzed by immunohisto-
chemistry. GR protein is expressed in vehicle-treated 
GRCaMKCreERT2 mice (A, D, G, J, M), whereas loss of GR 
expression upon tamoxifen treatment is observed in brain 
regions (B, E, H, K, N) that display strong CreERT2 expres-
sion (C, F, I, L, O). The analyzed GRCaMKCreERT2 mice harbor 
two copies of the CaMKCreERT2 transgene. Depicted are 
brain regions that have been identified as target regions using 
ROSA26 reporter mice and/or show strong GR expression 
in controls: cortex (A-C), CA1 region of the hippocampus 
(D-F), dentate gyrus (G-I), PVN (J-L) as well as central (ceA) 
and basolateral amygdala (blA) (M-O). The animals were 
injected with 1 mg tamoxifen or vehicle twice a day for five 
consecutive days and sacrificed ten days after the last injec-
tion. In addition, Cre transgenic mice were injected with 
tamoxifen 12 hours before analysis to obtain a nuclear stain-
ing for the CreERT2 fusion protein.BMC Neuroscience 2007, 8:63 http://www.biomedcentral.com/1471-2202/8/63
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Effect of variations in transgene copy number and the 
applied tamoxifen dose on GR protein loss
It has been shown previously that efficient induction of
recombination is dependent on the applied tamoxifen
dose and the level of CreERT2expression as well as on the
particular conditional allele [16,20,30]. Thus it is possi-
ble, that different conditional alleles require different lev-
els of CreERT2 activity. The level of CreERT2 activity is
dependent on the expression level of the CreERT2 protein
and on the availability of tamoxifen. Since the
CaMKCreERT2 transgene shows copy number-dependent
CreERT2 expression, we determined if we can detect an
interrelation of transgene copy number and tamoxifen
dose for the recombination evoked by this transgene. For
this purpose, we injected GRCaMKCreERT2 mice harboring
one, two or four copies of the transgene with 1 mg
tamoxifen for five consecutive days once per day (5 mg) or
twice per day (10 mg) and analyzed the loss of GR protein
in hippocampus, cortex and PVN.
The immunohistochemical analysis of the pyramidal neu-
rons of the hippocampal CA1 region revealed that
tamoxifen-treated controls (GRflox/flox, Fig. 4A and 4B)
show no difference in GR protein expression compared to
wild-type mice (data not shown). GRCaMKCreERT2 mice with
one copy of the transgene (Fig. 4C) show moderate loss of
GR signal after applying 5 mg tamoxifen, but a strong
decrease of GR protein if 10 mg tamoxifen were injected
(Fig. 4D). Mutant mice with two CaMKCreERT2 copies
treated with 5 mg tamoxifen also show a strong but
incomplete loss of GR protein (Fig. 4E), comparable to
one-copy animals treated with 10 mg tamoxifen (Fig. 4D).
GRCaMKCreERT2 animals with two and four copies of the
transgene display a complete loss of GR after injection of
10 mg tamoxifen (Fig. 4F and 4H). Likewise,
GRCaMKCreERT2  mice with four copies of the transgene
treated with 5 mg tamoxifen show complete GR loss in
pyramidal neurons of the hippocampal CA1 region (Fig.
4G). The same correlation between copy number and lig-
and dose was observed in the dentate gyrus of the hippoc-
ampus and in the cortex (data not shown). However, in
the PVN complete loss of GR signal was detected upon
injection of 10 mg tamoxifen in the presence of two or
four copies only, but none of the lines showed complete
GR loss if 5 mg were applied (data not shown). Taken
together, these data demonstrate that increasing copies of
the transgene reduce the tamoxifen dose required to
achieve recombination.
It has been shown previously, that ablation of GR protein
in neurons and glia cells results in a strong elevation of
plasma corticosterone [29]. The adrenal release of corti-
costerone is controlled by the hypothalamic-pituitary-
adrenal (HPA) axis. The feedback regulation of the HPA
axis is mediated by GR at the level of the pituitary and
PVN [31]. Since the PVN can be targeted with the
CaMKCreERT2 transgene, the measurement of plasma cor-
ticosterone provides information about the efficiency of
the GR ablation using the CaMKCreERT2 transgene. There-
fore, we measured plasma corticosterone of GRCaMKCreERT2
animals harboring one, two or four copies of the trans-
gene and their littermate controls (GRflox/flox) at the circa-
CreERT2-mediated recombination within the adult hippocam- pus depends on the transgene copy number and the  tamoxifen dose Figure 4
CreERT2-mediated recombination within the adult 
hippocampus depends on the transgene copy 
number and the tamoxifen dose. Pyramidal neurons in 
the hippocampal CA1 region of GRCaMKCreERT2 and control 
animals were analyzed by immunohistochemistry on 
vibratome-sections using an antibody against GR. Mice were 
injected with tamoxifen for five consecutive days either once 
per day (5 mg) (A, C, E, G) or twice per day (10 mg) (B, D, F, 
H) and sacrificed ten days after the last injection. Treatment 
with 5 mg tamoxifen results in an incomplete loss of GR pro-
tein if one or two copies of the CaMKCreERT2 transgene are 
present (C, E), whereas four copies of the transgene are suf-
ficient to induce complete GR protein loss (G). 
GRCaMKCreERT2 mice harboring two or four copies of the Cre 
transgene display complete loss of GR protein after injection 
of 10 mg tamoxifen (F, H). A visible but still incomplete loss 
of GR protein was seen in CaMKCreERT2 transgenic mice of 
the one-copy line treated with 10 mg tamoxifen (D) whereas 
tamoxifen-treated controls show no apparent loss of GR (A, 
B).BMC Neuroscience 2007, 8:63 http://www.biomedcentral.com/1471-2202/8/63
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dian trough. All animals were injected with 1 mg
tamoxifen twice a day for five consecutive days and sacri-
ficed six weeks after the treatment. The mutant mice from
all three lines show, as expected, a significant elevation of
plasma corticosterone compared to controls (Table 1).
Mutant mice, harboring one copy of the transgene display
a significant, but rather mild elevation of corticosterone.
GRCaMKCreERT2 mice with two and four copies of the trans-
gene exhibit an equivalent and compared to mutant ani-
mals with one copy of the transgene a stronger elevation
of the morning corticosterone level (Table 1).
Discussion
Brain-specific gene inactivation using the Cre/loxP-recom-
bination system allows to investigate gene function in the
adult brain in case the germline inactivation of the gene of
interest causes lethality. However, most of the available
brain-specific Cre-lines show onset of Cre expression
before the development of the brain is completed
[6,29,32]. Therefore, phenotypical changes can result
from interferences during brain development and/or from
deficiency of the respective protein in the adult brain [11].
To achieve a spatio-temporal control of Cre-mediated
recombination in the adult brain, regulatory elements of
the CaMKIIα gene have been already used to drive the
expression of different Cre fusion proteins. The fusion of
Cre recombinase with a modified ligand-binding domain
(LBD) of a steroid hormone receptor (e.g. progesterone
receptor or estrogen receptor) allows to regulate nuclear
translocation and thereby activity of the Cre recombinase
by administration of the cognate ligand. Expression of Cre
recombinase fused to a mutated form of the human pro-
gesterone receptor-LBD resulted in incomplete recombi-
nation within the hippocampal cornu ammonis and the
cortex upon RU 486 treatment, but no recombination was
observed in the dentate gyrus [14]. The fusion of a
mutated ligand-binding domain of the estrogen receptor
(ERT2) [13] onto both ends of the Cre recombinase,
expressed under the control of the regulatory elements of
the CaMKIIα gene, resulted in very weak recombination
efficiency (5%–10% in hippocampal pyramidal and gran-
ular neurons) upon tamoxifen treatment [33]. The fusion
of one ERT2 to the C-terminal end of Cre recombinase [13]
has been recently employed in oligodendrocytes, astro-
cytes and neural stem cells [20-24]. We have now gener-
ated transgenic mouse lines expressing the CreERT2fusion
protein under the control of regulatory elements of the
mouse CaMKIIα gene present on a large genomic DNA
fragment isolated from a BAC library. This transgene
allows highly efficient recombination of conditional
genes in brain regions shown to be important for learning,
memory and synaptic plasticity.
The CaMKCreERT2 transgene displays forebrain-specific, 
copy number-dependent expression and permits inducible 
site-specific recombination
The use of plasmid-derived transgenes that contain small
promoter fragments in front of an expression cassette
results in copy number-independent transgene expres-
sion. In addition, variable degrees of ectopic and mosaic
expression of the transgene is observed [9,10,34]. The use
of BAC or YAC clones, that contain large regions of
genomic DNA with almost all regulatory elements of the
gene with desired expression in their native configuration,
allows expression of the transgene that resembles the
expression of the endogenous gene independent of the
integration site [27,35,36]. Using the regulatory elements
of the mouse CaMKIIα gene we have generated transgenic
mice expressing the CreERT2 fusion protein in neurons of
the adult forebrain. We obtained different lines harboring
one, two or four copies of the transgene. As expected, the
expression pattern of the transgene is identical in all ana-
lyzed transgenic lines and shows only copy number-
dependent differences at the level of expression.
Using the ROSA26 Cre reporter we demonstrated the
effective temporal regulation of CreERT2  activity by
tamoxifen treatment in all three lines. In absence of the
ligand noteworthy constitutive recombination occurs
only within the dentate gyrus. Application of tamoxifen
results in strong recombination within forebrain regions
like hippocampus and cortex. Using the two-copy line we
compared the degree of recombination with the one elic-
ited by the constitutive CaMKCre line. Analysis of β-galac-
tosidase stainings of double transgenic animals harboring
a ROSA26 Cre reporter allele and the constitutively active
CaMKCre revealed recombination in the entire brain.
However, brain regions that show recombination in both,
the constitutive and the inducible Cre transgene after
tamoxifen treatment, display in the adult brain (ten
weeks) a comparable degree of recombination when
quantified by Southern blot. Since both transgenic lines
show similar Cre expression, independent of the develop-
mental stage, the observed differences in recombination
Table 1: Plasma corticosterone level [ng/ml] of adult tamoxifen-
treated GRCaMKCreERT2 mice at diurnal trough
line control mutant vs. one copy vs. two copies
one copy 13 ± 5 39 ± 8*
n = 7 n = 9
two copies 8 ± 1 100 ± 20* p < 0.05
n = 7 n = 9
four copies 15 ± 6 108 ± 19* p < 0.05 p = 0.75
n = 5 n = 5
control = GRflox/flox, mutant = GRflox/flox/CaMKCreERT2 transgene
* p < 0.05, control versus mutantBMC Neuroscience 2007, 8:63 http://www.biomedcentral.com/1471-2202/8/63
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pattern result from the different time period of nuclear
Cre activity of both transgenes. Using a ROSA26 Cre
reporter, we observe in case of the constitutive CaMKCre
transgene the accumulated recombination and thereby β-
galactosidase staining in all cells where Cre was active dur-
ing development and adulthood until dispatch. There-
fore, brain regions that show no or only weak Cre
expression at the adult stage can nevertheless show β-
galactosidase staining. In case of the CaMKCreERT2 trans-
gene Cre is only transiently activated during the presence
of tamoxifen. Thus the pattern of recombination reflects
CreERT2 expression within this time period only.
Inducible ablation of GR protein expression in the adult 
brain depends on the copy number of the Cre transgene 
and the tamoxifen dose
We successfully employed the CaMKCreERT2 transgene in
combination with a conditional GR allele (GRCaMKCreERT2
mice, two copies of the CreERT2 transgene) to achieve
ablation of GR in neurons of the adult forebrain. Upon
tamoxifen treatment, GRCaMKCreERT2 mice show loss of GR
protein, whereas vehicle-treated mutants showed no alter-
ations in GR expression compared to wild-type mice,
reflecting the very low background activity of the
CaMKCreERT2 transgene. In addition, we demonstrate for
the hippocampus that an increase in transgene copy num-
bers allows the reduction of the tamoxifen dose required
to achieve complete recombination.
Using the conditional GR allele we could show that using
the two- or four-copy line of the CaMKCreERT2 transgene
in combination with the injection of 1 mg tamoxifen
twice per day for five consecutive days results in similar
recombination efficiency, leading to complete loss of GR
protein in the cortex, hippocampus, PVN and basolateral
amygdala as well as a comparable increase of plasma cor-
ticosterone. Using the same tamoxifen dose the one-copy
line displays only partial loss of GR protein in PVN and
hippocampus resulting in a milder increase of plasma cor-
ticosterone. Since BAC-derived large genomic DNA frag-
ments potentially carry additional genes we will use for
further analyses of GRCaMKCreERT2 mice two copies of the
CaMKCreERT2 transgene and apply 1 mg tamoxifen twice
per day for five consecutive days. Moreover, we could
induce MR protein loss upon the identical tamoxifen
treatment in the brain regions targeted by the
CaMKCreERT2 transgene using the two-copy line in com-
bination with a conditional MR allele [11] (unpublished
observation). However, other conditional alleles may
require the use of four copies of the CaMKCreERT2 trans-
gene in combination with the injection of 1 mg tamoxifen
twice per day for five consecutive days, to achieve com-
plete recombination.
Conclusion
The expression of the CreERT2-fusion protein under con-
trol of the regulatory elements of the CaMKIIα gene
(CaMKCreERT2 transgene) allows inducible gene inactiva-
tion in neurons of the adult forebrain with very low back-
ground activity and highly efficient targeting upon
tamoxifen treatment. The use of a BAC-based transgene
resulted in a reliable and copy number-dependent trans-
gene expression. By employing the CaMKCreERT2 trans-
gene in combination with a conditional GR allele we were
able to induce spatially and temporally restricted loss of
GR protein dependent on transgene copy number and
applied tamoxifen dose.
Methods
Generation of CaMKCreERT2 transgenic mice
A bacterial artificial chromosome (BAC) harboring 143 kb
of genomic DNA (RP24-243J21) was chosen from the
mouse genome project [25]. The genomic DNA-fragment
contains, similar to the one used to generate a constitutive
CaMKCre transgene [27], the mouse CaMKIIα locus with
a 43 kb 5'upstream and a 100 kb 3'downstream region.
This BAC was modified by homologous recombination to
insert a cassette encoding a fusion protein (CreERT2) con-
sisting of a codon-improved Cre recombinase (Cre) [37]
and a mutated ligand-binding domain of the human
estrogen receptor (ERT2) [13] as well as an ampicillin
resistance cassette flanked by two FRT sites. The linear
construct was electroporated into heat-induced EL250
bacteria [26] harboring the BAC. Clones with the recom-
binant BAC were induced with L-arabinose to express Flp
recombinase that results in deletion of the ampicillin
resistance cassette [26]. The modified genomic fragment
containing the CreERT2 knock-in at the ATG of the CaM-
KIIα gene was separated from the BAC backbone by NotI
digestion and subsequent preparative pulse-field gel elec-
trophoresis. The DNA was purified from the gel slice and
microinjected into the pronucleus of FVB/N mouse
oocytes [38]. Transgenic offspring (founder) was identi-
fied by dot blot of tail DNA. A fragment of the coding
sequence of Cre was labeled and used as probe. Founder
mice were bred with C57Bl/6 mice to generate BAC-trans-
genic (CaMKCreERT2) mouse lines. Three different lines
with one, two and four copies of the transgene were ana-
lyzed. The Cre-transgenic mice were bred with ROSA26
Cre reporter mice or with mice harboring a conditional
GR allele (GRflox) [29] to generate the respective geno-
types used for the experiments.
Animal-treatment
Tamoxifen (Sigma) was dissolved in sunflower seed oil/
ethanol (10:1) mixture at a final concentration of 10 mg/
ml. Eight weeks old mice were injected intraperitoneally
with 1 mg of tamoxifen either once or twice per day for
five consecutive days. Control animals were injected withBMC Neuroscience 2007, 8:63 http://www.biomedcentral.com/1471-2202/8/63
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100 μl of sunflower seed oil/ethanol mixture (vehicle). If
not otherwise specified, control and mutant mice pos-
sessed the same genotype, but differed in the treatment
(control: vehicle, mutant: tamoxifen). Experimental ani-
mals for immunohistochemistry and Cre reporter analysis
were sacrificed ten days after the last injection. For corti-
costerone measurement GRflox/flox (control) and GRflox/flox/
CaMKCreERT2 (mutant) mice were both treated with 1 mg
tamoxifen twice a day for five consecutive days and were
sacrificed six weeks after the last injection to allow recov-
ery from the tamoxifen treatment.
Corticosterone measurement
To determine plasma corticosterone, adult mice (14
weeks) were housed individually one week before the
experiment (light on 9:00 – 21:00). Blood sampling was
performed in the morning (starting at 10:00) by bleeding
after decapitation, with the time from first handling to
decapitation not exceeding 20 s, to determine plasma cor-
ticosterone at circadian trough. Plasma corticosterone was
measured using a commercially available RIA kit (MP Bio-
medicals). Results are presented as mean ± SEM and were
analyzed using unpaired, two-tailed Student's t test.
Immunohistochemistry and β-galactosidase staining
For immunohistochemical analysis, the dissected brains
were postfixed with 4% paraformaldehyde at 4°C for 72
hrs. Coronal sections with a thickness of 50 μm were per-
formed using a vibratome (Microm). The floating sections
were processed for immunohistochemistry using the
VECTASTAIN ABC system (Vector Laboratories) and
diaminobenzidine (Sigma) incubation. Following pri-
mary antibodies have been used: polyclonal anti-Cre
(diluted 1:3000) [14] and polyclonal anti-GR (diluted
1:1000) (Santa Cruz Biotechnology).
For  β-galactosidase whole mount stainings, dissected
brains were cut with a razor blade in the appropriate
planes, washed three times with washing buffer (1 × PBS,
5 mM EGTA, 2 mM MgCl2, 0.01% sodium-deoxycholat
and 0.02% NP-40) and were subsequently stained with X-
gal staining solution (5 mM EGTA, 2 mM MgCl2, 0.01%
sodium-deoxycholat, 0.02% NP-40, 10 mM K3 [Fe(CN)6],
10 mM K4 [Fe(CN)6] and 0.5 mg/ml X-gal in 1 × PBS) at
37°C over night. After the staining slices were postfixed
with 4% paraformaldehyde at 4°C over night and kept in
1 × PBS at 4°C for analysis. For β-galactosidase staining of
cryosections, dissected brains were frozen in O.C.T. com-
pound (Tissue Tek, Sakura Finetek) on ethanol/dry ice
and 10 μm sagital cryosections were prepared. Sections
were fixed 10 min in 4% paraformaldehyde and β-galac-
tosidase staining was performed as described for whole
mount samples. Afterwards, sections were counterstained
with nuclear fast red (Sigma) and mounted with Eukitt
(O. Kindler).
Analysis of transgene copy numbers and quantification of 
recombination
Transgene copy number was determined by Southern blot
of tail DNA digested with BamHI and hybridized with a
DNA probe detecting sequences in the CaMKIIα promo-
tor region. The probe was labeled by random-priming
with α-32PdCTP. Relative band intensities were assessed
by phosphoimager (Fuji) and the band originating from
the endogenous CaMKIIα gene was calculated as two cop-
ies.
For analysis of Cre-mediated recombination, genomic
DNA was isolated from different brain areas. The DNA
was digested with SacI, blotted and hybridized with a
probe detecting in case of the GRflox and the GRwt allele a
fragment of similar size (7 kb) and in case of the GRnull
allele a smaller fragment (4.8 kb). Signals were quantified
by phosphoimager (Fuji) and percentage of recombina-
tion is calculated as signal intensity of the GRnull band
divided by the sum of the signal intensities of the GRflox/
GRwt band and GRnull band.
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